Market Overview

Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley

Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley

Insmed Incorporated (NASDAQ: INSM), an orphan disease company developing treatment for nontuberculous mycobacterial lung disease, is likely to see upside from maintenance therapy and its sales opportunity in Japan, according to Morgan Stanley. 

The Analyst

Analyst Matthew Harrison initiated coverage of Insmed with an Overweight rating and $39 price target, suggesting roughly 60-percent upside from current levels.

The Thesis

Insmed has longer-term optionality through frontline treatment, while clarity on label expansion should drive upside in the near-term, Harrison said in a Wednesday note.

The "novel" technology the company uses to deliver antibiotics to treat disease — antibiotics that are otherwise too toxic to systematically administer — can drive a pipeline of treatments for a variety of lung diseases, the analyst said. The vast majority of value in the near-to-medium-term is likely to generated in NTM, Harrison said. 

Morgan Stanley estimates there are 30,000 patients in the U.S. and Japan who are refractory to current treatments, equating to an initial global market of $700 million. 

Clean top-line data released in September is strong enough to generate $400 million to $500 million of peak U.S. sales, the analyst said. Insmed's valuation reflects only the U.S. refractory opportunity, Harrison said. 

"We believe the key upside drivers for INSM are expansion into maintenance therapy, geographic expansion to Japan and potentially even frontline treatment." 

The firm estimates Japan to be a $200 million to $300 million market, with a high number of identified patients.

Another study is needed to access frontline patients, Harrison said. 

The pressure on Insmed stock is due to higher-than-expected spending and the consensus view for a modest launch but the consensus is missing a peak sales opportunity that could be illuminated by an advisory committee and longer-term follow-up data, according to Morgan Stanley. 

The Price Action

Insmed shares are up about 50 percent over the past year.

The stock was up 4.14 percent after the open Wednesday.

Related Links:

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

7 Biotech Stocks With Clinical Trial Outcomes In March

Latest Ratings for INSM

Nov 2020Evercore ISI GroupReinstatesOutperform
Nov 2020Morgan StanleyMaintainsOverweight
Oct 2020StifelReinstatesBuy

View More Analyst Ratings for INSM
View the Latest Analyst Ratings


Related Articles (INSM)

View Comments and Join the Discussion!

Posted-In: David Lebowitz Morgan StanleyAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at